BACKGROUND: The long-term outcome of COVID-19-associated collapsing glomerulopathy is unknown. METHODS: We retrospectively identified 76 native kidney biopsies from patients with history of COVID-19 between March 2020 and April 2021. Presenting and outcome data were obtained for all 23 patients with collapsing glomerulopathy and for seven patients with noncollapsing podocytopathies. We performed APOL1 genotyping by Sanger sequencing, immunostaining for spike and nucleocapsid proteins, and in situ hybridization for SARS-CoV-2. RESULTS: The 23 patients with COVID-19-associated collapsing glomerulopathy were median age 57 years (range, 35-72), included 16 men, and were predominantly (91%) Black. Severity of COVID-19 was mild or moderate in most (77%) patients. All but one patient presented with AKI, 17 had nephrotic-range proteinuria, and six had nephrotic syndrome. Fourteen (61%) patients required dialysis at presentation. Among 17 patients genotyped, 16 (94%) were high-risk APOL1. Among 22 (96%) patients with median follow-up at 155 days (range, 30-412), 11 (50%) received treatment for COVID-19, and eight (36%) received glucocorticoid therapy for podocytopathy. At follow-up, 19 (86%) patients were alive, and 15 (68%) were dialysis free, including seven of 14 who initially required dialysis. The dialysis-free patients included 64% (seven of 11) of those treated for COVID-19 and 75% (six of eight) of those treated with glucocorticoids for podocytopathy. Overall, 36% achieved partial remission of proteinuria, 32% had no remission, and 32% reached combined end points of ESKD or death. Viral infection of the kidney was not detected. CONCLUSIONS: Half of 14 patients with COVID-19-associated collapsing glomerulopathy requiring dialysis achieved dialysis independence, but the long-term prognosis of residual proteinuric CKD remains guarded, indicating a need for more effective therapy.
BACKGROUND: The long-term outcome of COVID-19-associated collapsing glomerulopathy is unknown. METHODS: We retrospectively identified 76 native kidney biopsies from patients with history of COVID-19 between March 2020 and April 2021. Presenting and outcome data were obtained for all 23 patients with collapsing glomerulopathy and for seven patients with noncollapsing podocytopathies. We performed APOL1 genotyping by Sanger sequencing, immunostaining for spike and nucleocapsid proteins, and in situ hybridization for SARS-CoV-2. RESULTS: The 23 patients with COVID-19-associated collapsing glomerulopathy were median age 57 years (range, 35-72), included 16 men, and were predominantly (91%) Black. Severity of COVID-19 was mild or moderate in most (77%) patients. All but one patient presented with AKI, 17 had nephrotic-range proteinuria, and six had nephrotic syndrome. Fourteen (61%) patients required dialysis at presentation. Among 17 patients genotyped, 16 (94%) were high-risk APOL1. Among 22 (96%) patients with median follow-up at 155 days (range, 30-412), 11 (50%) received treatment for COVID-19, and eight (36%) received glucocorticoid therapy for podocytopathy. At follow-up, 19 (86%) patients were alive, and 15 (68%) were dialysis free, including seven of 14 who initially required dialysis. The dialysis-free patients included 64% (seven of 11) of those treated for COVID-19 and 75% (six of eight) of those treated with glucocorticoids for podocytopathy. Overall, 36% achieved partial remission of proteinuria, 32% had no remission, and 32% reached combined end points of ESKD or death. Viral infection of the kidney was not detected. CONCLUSIONS: Half of 14 patients with COVID-19-associated collapsing glomerulopathy requiring dialysis achieved dialysis independence, but the long-term prognosis of residual proteinuric CKD remains guarded, indicating a need for more effective therapy.
Authors: Leslie A Bruggeman; Michael D Ross; Nozomu Tanji; Andrea Cara; Steven Dikman; Ronald E Gordon; Godfrey C Burns; Vivette D D'Agati; Jonathan A Winston; Mary E Klotman; Paul E Klotman Journal: J Am Soc Nephrol Date: 2000-11 Impact factor: 10.121
Authors: Mohamed G Atta; Joel E Gallant; M Hafizur Rahman; Nagapradeep Nagajothi; Lorraine C Racusen; Paul J Scheel; Derek M Fine Journal: Nephrol Dial Transplant Date: 2006-07-24 Impact factor: 5.992
Authors: Charles R Swanepoel; Mohamed G Atta; Vivette D D'Agati; Michelle M Estrella; Agnes B Fogo; Saraladevi Naicker; Frank A Post; Nicola Wearne; Cheryl A Winkler; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christina M Wyatt Journal: Kidney Int Date: 2018-02-03 Impact factor: 10.612
Authors: Yonatan Peleg; Satoru Kudose; Vivette D'Agati; Eric Siddall; Syeda Ahmad; Thomas Nickolas; Sergey Kisselev; Ali Gharavi; Pietro Canetta Journal: Kidney Int Rep Date: 2020-04-28
Authors: Shreeram Akilesh; Cynthia C Nast; Michifumi Yamashita; Kammi Henriksen; Vivek Charu; Megan L Troxell; Neeraja Kambham; Erika Bracamonte; Donald Houghton; Naila I Ahmed; Chyi Chyi Chong; Bijin Thajudeen; Shehzad Rehman; Firas Khoury; Jonathan E Zuckerman; Jeremy Gitomer; Parthassarathy C Raguram; Shanza Mujeeb; Ulrike Schwarze; M Brendan Shannon; Iris De Castro; Charles E Alpers; Behzad Najafian; Roberto F Nicosia; Nicole K Andeen; Kelly D Smith Journal: Am J Kidney Dis Date: 2020-10-10 Impact factor: 8.860
Authors: Luise Hassler; Fabiola Reyes; Matthew A Sparks; Paul Welling; Daniel Batlle Journal: Clin J Am Soc Nephrol Date: 2021-06-14 Impact factor: 8.237
Authors: Samih H Nasr; Mariam Priya Alexander; Lynn D Cornell; Loren Hernandez Herrera; Mary E Fidler; Samar M Said; Pingchuan Zhang; Christopher P Larsen; Sanjeev Sethi Journal: Am J Kidney Dis Date: 2020-11-18 Impact factor: 8.860
Authors: Francisco Gómez Preciado; Rosa Alejandra De Carvalho Ovalles; Sergi Codina; Laura Donadeu; Alexandre Favà; Laura Martinez Valenzuela; Diego Sandoval; Bárbara Fernández-Cidón; Oriol Bestard; Pedro Alia-Ramos; Montserrat Gomà; Edoardo Melilli; Josep M Cruzado Journal: J Clin Med Date: 2022-06-24 Impact factor: 4.964
Authors: Sarah E Nystrom; Guojie Li; Somenath Datta; Karen L Soldano; Daniel Silas; Astrid Weins; Gentzon Hall; David B Thomas; Opeyemi A Olabisi Journal: JCI Insight Date: 2022-06-08
Authors: Rachel K Cason; Anna Williams; Megan Chryst-Stangl; Guanghong Wu; Kinsie Huggins; Kaye E Brathwaite; Brandon M Lane; Larry A Greenbaum; Vivette D D'Agati; Rasheed A Gbadegesin Journal: Front Pediatr Date: 2022-07-07 Impact factor: 3.569